ROCHE
Updates & Highlights
How Roche’s US$700 Million Bexobrutideg Alliance Will Impact Nurix Therapeutics (NRIX) Investors
How Roche’s US$700 Million Bexobrutideg Alliance Will Impact Nurix Therapeutics (NRIX) Investors
simplywall.st · about 3 hours ago
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer T
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer T
GuruFocus · about 4 hours ago
FDA grants priority review to Roche's Tecentriq for stage III colon cancer (RHHBY:OTCMKTS)
FDA grants priority review to Roche's Tecentriq for stage III colon cancer (RHHBY:OTCMKTS)
Seeking Alpha · about 6 hours ago
Recent Openings
View all 1 jobsCulture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Parental Leave
Family-friendly policies
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Roche?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentHow Roche’s US$700 Million Bexobrutideg Alliance Will Impact Nurix Therapeutics (NRIX) Investors
How Roche’s US$700 Million Bexobrutideg Alliance Will Impact Nurix Therapeutics (NRIX) Investors
simplywall.st · about 3 hours ago
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer T
Roche (RHHBY) Seeks FDA Approval for Tecentriq in Colon Cancer T
GuruFocus · about 4 hours ago
FDA grants priority review to Roche's Tecentriq for stage III colon cancer (RHHBY:OTCMKTS)
FDA grants priority review to Roche's Tecentriq for stage III colon cancer (RHHBY:OTCMKTS)
Seeking Alpha · about 6 hours ago
Roche - FDA Grants Priority Review For Tecentriq For A Certain Type Of Stage III Colon Cancer
Roche - FDA Grants Priority Review For Tecentriq For A Certain Type Of Stage III Colon Cancer
TradingView · about 6 hours ago
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer
Yahoo Finance · about 6 hours ago
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies
PR Newswire · about 6 hours ago
Vote gives new life to effort to save Roche de Boeuf bridge
Vote gives new life to effort to save Roche de Boeuf bridge
WTOL · about 13 hours ago
Waterville takes ownership of Roche de Boeuf Bridge
Waterville takes ownership of Roche de Boeuf Bridge
Sent-trib · about 13 hours ago
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know (RHHBY)
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must Know (RHHBY)
Seeking Alpha · about 17 hours ago
Roche sticks with €600M diagnostics investment in Germany but warns of future risk
Roche sticks with €600M diagnostics investment in Germany but warns of future risk
Fierce Biotech · 2 days ago
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer
GSK inks $10.6B Nuvalent buyout to challenge Roche and Pfizer in lung cancer
Fierce Biotech · 2 days ago
Roche sticks to German investment after Eli Lilly cuts
Roche sticks to German investment after Eli Lilly cuts
Reuters · 2 days ago
Top Stock Reports for Amazon, Bank of America & Roche
Top Stock Reports for Amazon, Bank of America & Roche
Yahoo Finance · 3 days ago
Roche stakes $700M on Nurix’s protein-degrading drug
Roche stakes $700M on Nurix’s protein-degrading drug
BioPharma Dive · 3 days ago
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics
Roche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics
Reuters · 3 days ago
Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader
Roche makes up to $2.3B blood cancer play with Nurix’s protein degrader
BioSpace · 3 days ago
Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche
Nurix Therapeutics Stock (NRIX) Soars 40% After $2.3B Blood Cancer Deal with Roche
TipRanks · 3 days ago
NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market
NRIX Stock Surges Nearly 70% Premarket Today – Roche And Nurix’s Blood Cancer Drug Collaboration Can Tap A $41B Market
Yahoo Finance · 3 days ago
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
Roche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdown
Fierce Biotech · 3 days ago
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect
Fierce Biotech · 4 days ago